All In Biotech

Drug Trial Radar · NCT03055013

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 819 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

819

Actual

Start

Apr 28, 2017

Primary completion

May 24, 2023

Study completion Jun 9, 2031

Sponsor

Sponsor type
NIH
First posted
Feb 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent the cancer from returning. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.

Conditions

  • Metastatic Renal Cell Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage II Renal Cell Cancer AJCC v7
  • Stage III Renal Cell Cancer AJCC v7
  • Unclassified Renal Cell Carcinoma

Interventions

  • NephrectomyProcedure

    Undergo nephrectomy

  • NivolumabBiological

    Given IV

  • Patient ObservationOther

    Undergo observation

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free Survival (RFS) Rate at 5 YearsTime frame: Assessed at 20 weeks, 40 weeks, then every 3 months for patients <2 years from randomization, then every 6 months for 3 years

Locations

413 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Veterans Administration Medical Center - Birmingham

    Birmingham, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Community Cancer Institute

    Clovis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Kaiser Permanente-Ontario

    Ontario, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • VA Palo Alto Health Care System

    Palo Alto, California

  • Kaiser Permanente - Panorama City

    Panorama City, California

  • Eisenhower Medical Center

    Rancho Mirage, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Kaiser Permanente Downtown Commons

    Sacramento, California

  • Sutter Medical Center Sacramento

    Sacramento, California

Showing 40 of 413 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.